Revista de Oncología

, Volume 6, Issue 5, pp 314–320 | Cite as

Neoadjuvant chemotherapy in breast cancer

  • Laura G. Estévez
Sección Docente


Taking into account what we presently know aboaut neoadjuvant chemotherapyn in breast cancer, the following conclusions may be drawn:


Breast Cancer Paclitaxel Docetaxel Sentinel Lymph Node Clin Oncol 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Kaufmann M, von Minckwitz G, Smith R, et al. International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations. J Clin Oncol 2003;21(23):4469.CrossRefGoogle Scholar
  2. 2.
    Haagensen C, Stout A. Carcinoma of the breast. II. Criteria of operability. Ann Surg 1943;118:859–70.CrossRefGoogle Scholar
  3. 3.
    Hunt KK, Ames FC, Singletary SE, Buzdar AU, Hortobagyi GN. Locally advanced noninflammatory breast cancer. Surg Clin North Am 1996;76:393–410.CrossRefGoogle Scholar
  4. 4.
    De Lena M, Zucali R, Viganotti G, Valagussa P, Bonadonna G. Combined chemotherapy-radiotherapy approach in locally advanced (T3b-T4) breast cancer. Cancer Chemother Pharmacol 1978;1:53–9.CrossRefGoogle Scholar
  5. 5.
    Fisher B, Bryant J, Wolmark N, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998;16:2672–85.CrossRefGoogle Scholar
  6. 6.
    Jakesz R. Comparison of pre- vs postoperative chemotherapy in breast cancer patients: four-year results of Austrian Breast & Colorectal Cancer Study Group (ABCSG) Trial 7. Proc Am Soc Clin Oncol 2001;20:32a.Google Scholar
  7. 7.
    Makris A, Powles TJ, Ashley SE, et al. A reduction in the requirements for mastectomy in a randomised trial of neoadjuvant chemoendocrine therapy in primary breast cancer. Ann Oncol 1998;9:1179–84.CrossRefGoogle Scholar
  8. 8.
    Mauriac L, MacGrogan G, Avril A, et al. Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with a 124-month median follow-up. Institut Bergonie Bordeaux Groupe Sein (IBBGS). Ann Oncol 1999;10:47–52.CrossRefGoogle Scholar
  9. 9.
    Ragaz J, Baird R, Rebbeck PC, Trevisan C, Goldie J, Coldman A. Preoperative (neoadjuvant) versus postoperative adjuvant chemotherapy for stage I–II breast cancer. Long-term analysis of British Columbia randomized trial. Proc Am Soc Clin Oncol 1997;16:142a.Google Scholar
  10. 10.
    Scholl SM, Fourquet A, Asselain B, et al. Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: preliminary results of a randomised trial: S6. Eur J Cancer 1994;30:645–52.CrossRefGoogle Scholar
  11. 11.
    Semiglazov VF, Topuzov EE, Bavli JL, et al. Primary (neoadjuvant) chemotherapy and radiotherapy compared with primary radiotherapy alone in stage IIb–IIIa breast cancer. Ann Oncol 1994;7:591–5.CrossRefGoogle Scholar
  12. 12.
    Valero V, Buzdar AU, Kau S-W, et al. Pathologically involved axillary nodes following primary chemotherapy in locally advanced breast cancer is an early biological prognostic factor for long-term outcome in patients with LABC. Ann Oncol 2002;13(Suppl 5):37.Google Scholar
  13. 13.
    Henderson IC, Berry DA, Demetri GD, et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 2003;21(6):976–83.CrossRefGoogle Scholar
  14. 14.
    Nabothz JM, Pienkowski T, Mackey J, et al. Phase III Trial Comparing TAC (docetaxel, doxorubicin, cyclophosphamide) with FAC (5-fluorouracil, doxorubicin, cyclophosphamide) in the adjuvant treatment of node positive breast cancer (BC) patients: interim analysis of the BCIRG 001 Study. Proc Am Soc Clin Oncol 2002;21: 145a.Google Scholar
  15. 15.
    Singletary SE, Greene FL, Breast Task Force. Revision of breast cancer staging: the 6th edition of the TNM Classification. Semin Surg Oncol 2003;21(1):53–9.CrossRefGoogle Scholar
  16. 16.
    Bonadonna G, Veronesi U, Brambilla C, et al. Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more. J Natl Cancer Inst 1990;82(19):1539–45.CrossRefGoogle Scholar
  17. 17.
    Calais G, Berger C, Descamps P, et al. Conservative treatment feasibility with induction chemotherapy, surgery, and radiotherapy for patients with breast carcinoma larger than 3 cm. Cancer 1994;74(4):1283–8.CrossRefGoogle Scholar
  18. 18.
    Veronesi U, Bonadonna G, Zurrida S, et al. Conservation surgery after primary chemotherapy in large carcinomas of the breast. Ann Surg 1995;222(5):612–8.CrossRefGoogle Scholar
  19. 19.
    Danforth DN Jr, Lippman ME, McDonald H, et al. Effect of preoperative chemotherapy on mastectomy for locally advanced breast cancer. Am Surg 1990;56(1):6–11.PubMedGoogle Scholar
  20. 20.
    Morrow M, Bucci C, Rademaker A. Medical contraindications are not a major factor in the underutilization of breast conserving therapy. J Am Coll Surg 1998;186(3): 269–74.CrossRefGoogle Scholar
  21. 21.
    Chollet P, Amat S, Cure H, et al. Prognostic significance of a complete pathological response after induction chemotherapy in operable breast cancer. Br J Cancer 2002; 86:1041–6.CrossRefGoogle Scholar
  22. 22.
    Kuerer HM, Newman LA, Smith TL, et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 1999;17:460–9.CrossRefGoogle Scholar
  23. 23.
    Chevallier B, Roche H, Olivier JP, Chollet P, Hurteloup P. Pilot study of intensive induction chemotherapy (FEC-HD) results in a high histologic response rate. Am J Clin Oncol 1993;16:223–8.CrossRefGoogle Scholar
  24. 24.
    Honkoop AH, van Diest PJ, de Jong JS, et al. Prognostic role of clinical, pathological and biological characteristics in patients with locally advanced breast cancer. Br J Cancer 1998;77:621–6.CrossRefGoogle Scholar
  25. 25.
    Smith IA, Miller ID. Issues involved in research into the neoadjuvant treatment of breast cancer. Anticancer Drugs 2001;12(Suppl 1):S25–9.Google Scholar
  26. 26.
    Sataloff DM, Mason BA, Prestipino AJ, Seinige UL, Lieber CP, Baloch Z. Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome. J Am Coll Surg 1995;180: 297–306.PubMedGoogle Scholar
  27. 27.
    Bonadonna G, Valagussa P, Brambilla C, et al. Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute. J Clin Oncol 1998;16:93–100.CrossRefGoogle Scholar
  28. 28.
    Chang J, Powles TJ, Allred DC, et al. Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer. J Clin Oncol 1999; 17:3058–63.CrossRefGoogle Scholar
  29. 29.
    Gianni L, Baselga J, Eiermann W, et al, for the ECTO Study Group. First report of the European Cooperative Trial in Operable Breast Cancer (ECTO): effects of primary systemic therapy on local-regional disease. Proc Am Soc Clin Oncol 2002;21:34a.Google Scholar
  30. 30.
    Pierga JY, Mouret E, Dieras V, et al. Prognostic value of persistent node involvement after neoadjuvant chemotherapy in patients with operable breast cancer. Br J Cancer 2000;83:1480–7.CrossRefGoogle Scholar
  31. 31.
    Kandioler-Eckersberger D, Ludwig C, Rudas M, et al. TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients. Clin Cancer Res 2000;6:50–6.PubMedGoogle Scholar
  32. 32.
    Remvikos Y, Vielh P, Padoy E, Benyahia B, Voillemot N, Magdelenat H. Breast cancer proliferation measured on cytological samples: a study by flow cytometry of S-phase fractions and BrdU incorporation. Br J Cancer 1991; 64:501–7.CrossRefGoogle Scholar
  33. 33.
    Gregory RK, Powles TJ, Salter J, Chang JC, Ashley S, Dowsett M. Prognostic relevance of cerbB2 expression following neoadjuvant chemotherapy in patients in a randomised trial of neoadjuvant versus adjuvant chemoendocrine therapy. Breast Cancer Res Treat 2000;59: 171–5.CrossRefGoogle Scholar
  34. 34.
    Makris A, Powles TJ, Dowsett M, et al. Prediction of response to neoadjuvant chemoendocrine therapy in primary breast carcinomas. Clin Cancer Res 1997;3:593–600.PubMedGoogle Scholar
  35. 35.
    Willsher PC, Pinder SE, Gee JM, et al. c-erbB2 expression predicts response to preoperative chemotherapy for locally advanced breast cancer. Anticancer Res 1998; 18:3695–8.PubMedGoogle Scholar
  36. 36.
    Chang JC, Wooten EC, Tsimelzon A, et al. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 2003; 362:362–9.CrossRefGoogle Scholar
  37. 37.
    Pusztai L, Ayers M, Simmans FW, et al. Emerging science: prospective validation of gene expression profiling-based prediction of complete pathologic response to neoadjuvant paclitaxel/FAC chemotherapy in breast cancer. Proc Am Soc Clin Oncol 2003;22:1a.Google Scholar
  38. 38.
    Nabholtz JM, Tonkin K, Smylie M, Au HJ, Lindsay MA, Mackey J. Chemotherapy of breast cancer: are the taxanes going to change the natural history of breast cancer? Exp Opin Pharmacother 2000;1:187–206.CrossRefGoogle Scholar
  39. 39.
    De Matteis A, Nuzzo F, D'Aiuto G, et al. docetaxel plus epidoxorubicin as neoadjuvant treatment in patients with large operable or locally advanced carcinoma of the breast. A single-center, phase II study. Cancer 2002;94:895–901.CrossRefGoogle Scholar
  40. 40.
    Baltali E, Altundag MK, Onat DA, et al. Neoadjuvant chemotherapy with taxotere-epirubicin-5-fluorouracil (TEF) in local-regionally advanced breast cancer: a preliminary report. Tumori 2002;88:474–7.PubMedGoogle Scholar
  41. 41.
    Wenzel C, Locker GJ, Schmidinger M, et al. Combined analysis of two phase II trials in patients with primary and advanced breast cancer with epidoxorubicin and docetaxel+granulocyte colony-stimulating factor. Anticancer Drugs 2002;13:67–74.CrossRefGoogle Scholar
  42. 42.
    Tubiana-Hulin M, Dieras V, Fumoleau P, et al. Phase II trial combining docetaxel and doxorubicin in the neoadjuvant setting in patients with operable breast carcinoma: final results. Breast Cancer Res Treat 2000;64:250.Google Scholar
  43. 43.
    Valero V, Esteva FJ, Sahin AA, et al. Phase II trial of neoadjuvant chemotherapy with docetaxel and doxorubicin, surgery, adjuvant CMF, and radiotherapy +/-tamoxifen in locally advanced breast cancer. Breast Cancer Res Treat 2000;64:69.Google Scholar
  44. 44.
    von Minckwitz G, Costa SD, Eiermann W, et al. Maximized reduction of primary breast tumor size using preoperative chemotherapy with doxorubicin and docetaxel. J Clin Oncol 1999;17:1999–2005.CrossRefGoogle Scholar
  45. 45.
    Gogas H, Papadimitriou C, Kalofonos HP, et al. Neoadjuvant chemotherapy with a combination of pegylated liposomal doxorubicin (Caelyx) and paclitaxel in locally advanced breast cancer: a phase II study by the Hellenic Cooperative Oncology Group. Ann Oncol 2002;13:1737–42.CrossRefGoogle Scholar
  46. 46.
    Sánchez-Rovira P, Jaén A, Dueñas R, et al. Primary chemotherapy in locally advanced breast cancer with gemcitabine, adriamycin and paclitaxel. A phase II trial and predictive value of Erb2. Proc Am Soc Clin Oncol 2001; 29:31b.Google Scholar
  47. 47.
    Sánchez-Rovira P, Jaen A, Duenas R, et al. Neoadjuvant gemcitabine therapy for breast cancer. Clin Breast Cancer 2002;3(Suppl 1):S39–44.CrossRefGoogle Scholar
  48. 48.
    Sousa GC. Neoadjuvant chemotherapy of locally advanced breast cancer: a phase II trial of epirubicin, cyclophosphamide and paclitaxel. Acta Oncol 2002;13(Suppl 5):54.Google Scholar
  49. 49.
    Bellino R, Cortese P, Danese S, et al. Epidoxorubicin and paclitaxel as primary chemotherapy for T>3 cm and T4 breast cancer patients. Anticancer Res 2000;20:4825–8.PubMedGoogle Scholar
  50. 50.
    Moliterni A, Tarenzi E, Capri G, et al. Pilot study of primary chemotherapy with doxorubicin plus paclitaxel in women with locally advanced or operable breast cancer. Semin Oncol 1997;24(Suppl 17):10–14.Google Scholar
  51. 51.
    Semiglazov VF, Bojok AA, Arsumanov AS, et al. Breast conserving surgery after neoadjuvant chemotherapy paclitaxel + doxorubicin vs fluorouracil + doxorubicin + cyclophosphamide. Proc San Antonio 2002;76(Suppl 1): S52.Google Scholar
  52. 52.
    Green MC, Buzdar AU, Smith T, et al. Weekly paclitaxel followed by FAC as primary systemic chemotherapy of operable breast cancer improves pathologic complete remission rates when compared to every 3-week paclitaxel therapy followed by FAC — final results of a prospective phase III randomized trial. Proc Am Soc Clin Oncol 2002;21:35a.Google Scholar
  53. 53.
    Bear HD, Anderson S, Brown A, et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 2003;21:4165–74.CrossRefGoogle Scholar
  54. 54.
    Smith IC, Heys SD, Hutcheon AW, et al. Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol 2002;20:1456–66.CrossRefGoogle Scholar
  55. 55.
    Breslin TM, Cohen L, Sahin A, et al. Sentinel lymph node biopsy is accurate after neoadjuvant chemotherapy for breast cancer. J Clin Oncol 2000;18:3480–6.CrossRefGoogle Scholar

Copyright information

© FESEO 2004

Authors and Affiliations

  • Laura G. Estévez
    • 1
  1. 1.Servicio de Oncología MédicaFundación Jiménez DíazMadridSpain

Personalised recommendations